This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Trial of clozapine in refractory schizophrenia

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

423 hospitalised patients with refractory schizophrenia were randomised to clozapine or standard treatment with haloperidol.

57% of clozapine patients and 61% of haloperidol patients continued with the assigned drug for the whole year.

Clozapine patients had 5.4% lower symptom scores (score 79.1 vs. 83.6, P=0.02).

Clozapine patients needed fewer days of inpatient treatment (143.8 vs. 168.1, P=0.03).

Despite a higher drug bill in the clozapine group the annual total cost was less because of the fewer inpatient days.

Reference:

  • Rosenheck R. et al (1997). A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. NEJM, 337, 809-15.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.